Cargando…

Better Outcome of Off-Label High-Dose Ceftazidime in Hemato-Oncological Patients with Infections Caused by Extensively Drug-Resistant Pseudomonas Aeruginosa

BACKGROUND: P. aeruginosa sepsis in immunocompromised patients is a serious complication of cancer treatment, especially in the case of an Extensively Drug Resistant (XDR) pathogen. The aim of the study is to evaluate the efficacy of high-dose ceftazidime in the treatment of XDR P. aeruginosa infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zavrelova, Alzbeta, Paterova, Pavla, Zak, Pavel, Visek, Benjamin, Sima, Martin, Radocha, Jakub
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833305/ https://www.ncbi.nlm.nih.gov/pubmed/36660352 http://dx.doi.org/10.4084/MJHID.2023.001

Ejemplares similares

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome
por: Belohlavkova, P, et al.
Publicado: (2021)

BAL fluid analysis in the identification of infectious agents in patients with hematological malignancies and pulmonary infiltrates
por: Zak, P., et al.
Publicado: (2019)

Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex
por: Ramsay, Kay A., et al.
Publicado: (2023)

Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients
por: Hricová, Kristýna, et al.
Publicado: (2020)

Stem Cells in Hemato-Oncology
por: Damodar, S
Publicado: (2006)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
por: Daikos, George L., et al.
Publicado: (2021)

Reversion of Ceftazidime Resistance in Pseudomonas aeruginosa under Clinical Setting
por: Liu, Qi, et al.
Publicado: (2022)

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
por: Montero, María M., et al.
Publicado: (2021)

Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema: A case report
por: Chen, Tzu-Ting, et al.
Publicado: (2022)

PRES in the course of hemato-oncological treatment in children
por: Musioł, Katarzyna, et al.
Publicado: (2017)

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
por: Caldwell, Louise, et al.
Publicado: (2022)

Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa
por: Zhang, Yulin, et al.
Publicado: (2022)

Severe Keratitis Caused by Pseudomonas aeruginosa Successfully Treated with Ceftazidime Associated with Acetazolamide
por: Hue, Benoit, et al.
Publicado: (2009)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms
por: Kamali, Esmat, et al.
Publicado: (2021)

Palestinian Children in the Hemato-Oncology Ward of an Israeli Hospital
por: Nehari, Miri, et al.
Publicado: (2008)

Monitoring of the Environment at the Transplant Unit—Hemato-Oncology Clinic
por: Matoušková, Ivanka, et al.
Publicado: (2014)

Hemato-oncology Tourism in Israel: A Retrospective Review
por: Hod, Keren, et al.
Publicado: (2020)

COVID-19 in Omani Children with Hemato-Oncology Diseases
por: Al Yazidi, Laila S, et al.
Publicado: (2020)

Comparison of efficiency of intravitreal ceftazidime and intravitreal cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis
por: Deniz, Nurettin, et al.
Publicado: (2013)

Continuous infusion versus intermittent infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa
por: Lorente, L, et al.
Publicado: (2005)

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
por: Zhu, Yiwei, et al.
Publicado: (2021)

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
por: Chen, Juan, et al.
Publicado: (2022)

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
por: Chen, Juan, et al.
Publicado: (2023)

Ceftazidime-assisted synthesis of ultrasmall chitosan nanoparticles for biofilm penetration and eradication of Pseudomonas aeruginosa
por: Zheng, Xiaoran, et al.
Publicado: (2023)

Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
por: Meschiari, Marianna, et al.
Publicado: (2020)

Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains
por: Torres, Ieda Maria Sapateiro, et al.
Publicado: (2012)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
por: Dai, Yuanyuan, et al.
Publicado: (2021)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
por: Wang, Leilei, et al.
Publicado: (2023)

Catheter-related bloodstream infections in hemato-oncology paediatric patients
por: Giamberardino, HIG, et al.
Publicado: (2015)

Platelet Septic Transfusion Reactions in Patients With Hemato-Oncological Diseases
por: Razjou, Farhad, et al.
Publicado: (2017)

Pediatric Hemato-Oncology Care Amid the COVID-19 Pandemic
por: Sahi, Puneet Kaur, et al.
Publicado: (2021)

Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro Evidence
por: Lopez-Montesinos, Inmaculada, et al.
Publicado: (2022)

Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium
por: Van Valckenborgh, Els, et al.
Publicado: (2018)

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
por: Sorf, Ales, et al.
Publicado: (2020)

Exoproteomics for Better Understanding Pseudomonas aeruginosa Virulence
por: Sauvage, Salomé, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mgpqb2t9eq2kg3lbitfeam47kb